Business Context and Reporting Period
This Form 8-K is filed by Imprimis Pharmaceuticals, Inc. (not Harrow, Inc., as indicated in the metadata) on November 12, 2018. The report discloses material information regarding a significant investment held by the registrant in Eton Pharmaceuticals, Inc.
Key Financial Metrics
The filing does not provide Imprimis Pharmaceuticals' own revenue, profit, cash flow, or debt metrics. The only financial data disclosed relates to the initial public offering (IPO) of Eton Pharmaceuticals, Inc.:
- Shares Offered: 3,600,000 shares of Eton common stock.
- Offering Price: $6.00 per share.
- Imprimis Ownership: Imprimis owns 3,500,000 shares of Eton common stock.
Material Changes
The material change reported is the pricing of Eton Pharmaceuticals' IPO. Eton's common stock was approved for listing on the Nasdaq Global Market under the ticker symbol "ETON," with trading expected to commence on November 13, 2018. The offering was expected to close on November 15, 2018, subject to customary conditions.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on Imprimis's operations, or specific risk factors beyond standard securities law disclaimers. The report explicitly states it does not constitute an offer to sell or a solicitation to buy Eton securities in jurisdictions where such actions would be unlawful.
Investor Verification Checklist
- Verify the closing of Eton Pharmaceuticals' IPO on or around November 15, 2018.
- Confirm the trading status of Eton stock under the ticker "ETON" on the Nasdaq Global Market.
- Review the full text of the Eton Pharmaceuticals press release (Exhibit 99.1) for details on underwriting and use of proceeds.
- Assess the impact of the Eton IPO valuation on Imprimis Pharmaceuticals' balance sheet and potential future liquidity.